Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy.
about
Melatonin: Characteristics, Concerns, and ProspectsNeurotoxins: free radical mechanisms and melatonin protectionA Radiobiological Review on Melatonin: A Novel RadioprotectorInternational Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.No effects of GSM-modulated 900 MHz electromagnetic fields on survival rate and spontaneous development of lymphoma in female AKR/J micePreventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague-Dawley ratA Comparative Study on Cancer Prevention Principles Between Iranian Traditional Medicine and Classic MedicineCommon sense: folk wisdom that ethnobiological and ethnomedical research cannot afford to ignore.Artificial light at night: melatonin as a mediator between the environment and epigenomeMelatonin in Alzheimer's disease and other neurodegenerative disordersThe dark side of light at night: physiological, epidemiological, and ecological consequencesTherapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapySelective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatoninA case-referent study: light at night and breast cancer risk in GeorgiaUrinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control studyNight shift work and levels of 6-sulfatoxymelatonin and cortisol in menInhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cellsRandomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119)Melatonin attenuates cisplatin-induced HepG2 cell death via the regulation of mTOR and ERCC1 expressions.Melatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer (Review).Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer.Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value.Melatonergic drugs in development.Short duration of sleep increases risk of colorectal adenomaMelatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model.Melatonin anticancer effects: reviewMelatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives.A biobehavioral perspective of tumor biologyThe influence of bio-behavioural factors on tumour biology: pathways and mechanisms.Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cellsCircadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night.Melatonin enhances photo-oxidation of 2',7'-dichlorodihydrofluorescein by an antioxidant reaction that renders N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK).Effects of exogenous melatonin--a review.Evaluation of the antioxidant effects of melatonin on the larynx mucosa of rats exposed to environmental tobacco smoke.5-Meth-oxy-1-[(5-meth-oxy-1H-indol-2-yl)meth-yl]-1H-indoleMelatonin: bone metabolism in oral cavity.CYP1A in TCDD toxicity and in physiology-with particular reference to CYP dependent arachidonic acid metabolism and other endogenous substrates.NMR and molecular dynamics studies of the interaction of melatonin with calmodulin.Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survivalLight, dark, and melatonin: emerging evidence for the importance of melatonin in ocular physiology.
P2860
Q22299303-34B6454B-15ED-4100-BAB3-ECB02C15BA9BQ22305781-99F75063-A04B-4EDF-A640-1DE730C9DD28Q22306143-4523CED8-5ADC-4AA2-BF38-24DDFDD6D0A1Q24623433-BBAA06D2-8619-4E79-B9DF-4307907B0E39Q24798982-B8843B16-761D-4A08-972C-4930442D993AQ24810633-23F8D630-7340-4A49-814A-214B57ECD438Q26747741-26523C5F-11F4-449B-A82E-5706BB53E6B8Q27690794-A65EA8B0-4C96-4604-A229-9AE1954454EFQ28085136-C0F755E0-64B3-4564-994C-4D8BEC663CBEQ28217483-2CC38EF9-F66D-4041-A4C1-D63263ECE6E6Q28246097-A5BDAEE6-8F95-48A5-A57F-E6B80923C83FQ28266443-E72D279E-4D6E-4955-AC6F-AC447E935D13Q28271296-BB0D4EC4-8CA5-4B0C-90C1-D1FE18AB7872Q28382853-CF32EEC8-560D-487F-A3BF-3C7BC52DC578Q28383609-12929343-9520-4324-ABC1-4D904D285ABFQ28388457-4FE89723-AC6B-418B-9D97-08A5FF69C331Q28580837-E584AB98-3676-4C71-A638-A6DF8536CE47Q30439202-92CAC1CC-ED9D-4FFF-A3BC-47C722E09166Q31160482-F53C507E-D41C-4188-B3C8-2386B82A5F7EQ33844198-7E5A0384-DE55-4217-B88C-5F56A3D8C47AQ34168873-7213A85E-3393-4805-905E-22269441AEC5Q34416921-CC7536D5-0C99-4C5C-BD8B-323F72B4736BQ34440574-8D6AF2D4-FC81-42D3-AE41-A915ED9C054CQ34490935-7E5DF6E3-BE0E-4EDC-8715-209960BD51DAQ34642163-2FB0F937-7366-45B1-B3F2-9B29937B6C99Q34647628-11B7FC70-87BF-4689-9019-2FFD6AFD4A11Q34994700-FAF5AACD-BB5A-4FFF-A471-2FE36299D06DQ35131708-C6B5394A-DFBD-4CE2-A231-60B9C96ED4C2Q35135129-54006409-74E1-4A1C-B765-B3EB5BA19681Q35172397-81CF6638-8B2C-4A6E-8532-C738CBEF0FCBQ35181910-96ED1936-DF27-40D7-B2E4-C2BDEE110EADQ35294224-F7C1E1CA-6CA9-45FF-8F58-C1747A4DF408Q35571585-84449D99-0843-4986-9709-CEE265402DB2Q35683400-959EFC16-A75F-495A-89A8-A9540912BD6EQ35933088-BACA50AF-D6A8-4A5C-AB98-ADCE6C2556FFQ36178389-CED13845-BE3A-4BB8-BF92-2244AA9DC299Q36473507-6678AE5F-FD37-4322-A802-25FD3C20D103Q36526298-E05124AF-B767-450E-B824-F86B1DF465E4Q36554668-B2BB350C-D3B5-44ED-B8C5-30823CE6BB76Q36603911-D0678DB6-9789-4058-91EE-B1FF2C6F0E01
P2860
Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Melatonin as a chronobiotic/an ...... ircadian-based cancer therapy.
@ast
Melatonin as a chronobiotic/an ...... ircadian-based cancer therapy.
@en
Melatonin as a chronobiotic/an ...... ircadian-based cancer therapy.
@nl
type
label
Melatonin as a chronobiotic/an ...... ircadian-based cancer therapy.
@ast
Melatonin as a chronobiotic/an ...... ircadian-based cancer therapy.
@en
Melatonin as a chronobiotic/an ...... ircadian-based cancer therapy.
@nl
prefLabel
Melatonin as a chronobiotic/an ...... ircadian-based cancer therapy.
@ast
Melatonin as a chronobiotic/an ...... ircadian-based cancer therapy.
@en
Melatonin as a chronobiotic/an ...... ircadian-based cancer therapy.
@nl
P356
P1476
Melatonin as a chronobiotic/an ...... ircadian-based cancer therapy.
@en
P2093
Leonard A Sauer
P304
P356
10.2174/1568026023394407
P577
2002-02-01T00:00:00Z